Table 2. EGFR p.T790M, PIK3CA and KRAS mutation in post-TKI specimens.
| p.T790M | PIK3CA | KRAS | No mutation | 2 or 3 mutations | |
|---|---|---|---|---|---|
| Patients (n = 39)a | 31 (79%)b | 10 (26%) | 1 (2.6%) | 6 (15%)e | 8 (21%) |
| adenocarcinoma (n = 37) | 31 (84%) | 9 (24%) | 1 (2.7%) | 5 (14%) | 8 (22%) |
| small cell carcinoma (n = 4)c | 0 | 2 (50%)d | 0 | 2 (67%) | 0 |
a
Including patient 19 with an adenocarcinoma specimen and a small cell carcinoma specimen.
b
including patient 2 with 1.1% p.T790M mutation.
c
including retrospective analysis of the small cell carcinoma specimen in the pleural effusion of patient 4.
d
The PIK3CA p.G1049R was present in the pre-TKI specimen of patient 4. The pre-TKI specimen of patient 29 was not tested.
e
including patient 11 with small cell carcinoma transformation.